1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. 2. Grade 3 or worse adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: A previous large-scale trial has shown improved overall survival among patients with cervical cancer treated with
The FDA has granted priority review to a supplemental biologics license application seeking to convert the accelerated approval of tisotumab vedotin to a full approval for the treatment of patients with recurrent or metastatic cervical cancer whose disease progresses on or following frontline therapy.
Clinical insights on treatment options for patients with newly diagnosed metastatic cervical cancer, with a focus on immunotherapy and the KEYNOTE-826 trial.